WO2011089168A3 - Special composition for the use thereof as a drug - Google Patents

Special composition for the use thereof as a drug Download PDF

Info

Publication number
WO2011089168A3
WO2011089168A3 PCT/EP2011/050715 EP2011050715W WO2011089168A3 WO 2011089168 A3 WO2011089168 A3 WO 2011089168A3 EP 2011050715 W EP2011050715 W EP 2011050715W WO 2011089168 A3 WO2011089168 A3 WO 2011089168A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
special composition
functional equivalent
composition
nutraceutical
Prior art date
Application number
PCT/EP2011/050715
Other languages
French (fr)
Other versions
WO2011089168A2 (en
Inventor
Remy Burcelin
Eric Seree
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Universite De La Mediterranee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Universite De La Mediterranee filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Priority to JP2012549351A priority Critical patent/JP2013518034A/en
Priority to CA2792993A priority patent/CA2792993A1/en
Priority to EP11700445A priority patent/EP2525791A2/en
Priority to US13/574,012 priority patent/US20130029996A1/en
Publication of WO2011089168A2 publication Critical patent/WO2011089168A2/en
Publication of WO2011089168A3 publication Critical patent/WO2011089168A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a composition containing at least one polyphenol, at least one polyethylene glycol and/or a functional equivalent, and at least one glycol ether and/or a functional equivalent for the use thereof as a drug. The composition according to the invention can also be used as a food supplement or nutraceutical.
PCT/EP2011/050715 2010-01-21 2011-01-20 Special composition for the use thereof as a drug WO2011089168A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012549351A JP2013518034A (en) 2010-01-21 2011-01-20 Special composition for use as a drug
CA2792993A CA2792993A1 (en) 2010-01-21 2011-01-20 Special composition for the use thereof as a drug
EP11700445A EP2525791A2 (en) 2010-01-21 2011-01-20 Special composition for the use thereof as a drug
US13/574,012 US20130029996A1 (en) 2010-01-21 2011-07-28 Special composition for the use thereof as a drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305071.2 2010-01-21
EP10305071 2010-01-21

Publications (2)

Publication Number Publication Date
WO2011089168A2 WO2011089168A2 (en) 2011-07-28
WO2011089168A3 true WO2011089168A3 (en) 2011-12-29

Family

ID=42076273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/050715 WO2011089168A2 (en) 2010-01-21 2011-01-20 Special composition for the use thereof as a drug

Country Status (5)

Country Link
US (1) US20130029996A1 (en)
EP (1) EP2525791A2 (en)
JP (1) JP2013518034A (en)
CA (1) CA2792993A1 (en)
WO (1) WO2011089168A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
WO2020144753A1 (en) * 2019-01-09 2020-07-16 公立大学法人大阪 Prophylactic or therapeutic drug for neurodegenerative diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030336A2 (en) * 1999-10-29 2001-05-03 Pharmascience Pharmaceutical formulations comprising resveratrol and use thereof
WO2008137787A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
WO2009039195A1 (en) * 2007-09-20 2009-03-26 Resveratrol Partners, Llc Resveratrol-containing compositions for modulating gene product concentration or activity
WO2010007252A2 (en) * 2008-07-18 2010-01-21 Yvery Formulation for improving the bioavailability of a hydrophobic molecule
WO2011039175A1 (en) * 2009-09-29 2011-04-07 Bodo Melnik Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61171427A (en) 1985-01-24 1986-08-02 Osaka Chem Lab Substance for preventing thrombosis or the like
JPS62192040A (en) 1986-02-19 1987-08-22 Canon Inc Optical information recording medium
JPH0624967B2 (en) 1989-08-15 1994-04-06 工業技術院長 Method for producing elastic graphite body
IT1276225B1 (en) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ALKANOYL L-CARNITINE IN ASSOCIATION WITH RESVERATROL OR ITS DERIVATIVES USEFUL FOR

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030336A2 (en) * 1999-10-29 2001-05-03 Pharmascience Pharmaceutical formulations comprising resveratrol and use thereof
WO2008137787A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
WO2009039195A1 (en) * 2007-09-20 2009-03-26 Resveratrol Partners, Llc Resveratrol-containing compositions for modulating gene product concentration or activity
WO2010007252A2 (en) * 2008-07-18 2010-01-21 Yvery Formulation for improving the bioavailability of a hydrophobic molecule
WO2011039175A1 (en) * 2009-09-29 2011-04-07 Bodo Melnik Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAS SAMARJIT: "Anti-inflammatory responses of resveratrol", INFLAMMATION & ALLERGY DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS LNKD- DOI:10.2174/187152807781696464, vol. 6, no. 3, 1 September 2007 (2007-09-01), pages 167 - 173, XP009120175, ISSN: 1871-5281 *
NADERALI ET AL: "Obesity and cardiovascular dysfunction: A role for resveratrol?", OBESITY RESEARCH & CLINICAL PRACTICE,, vol. 3, no. 1, 1 March 2009 (2009-03-01), pages 45 - 52, XP025941189, ISSN: 1871-403X, [retrieved on 20081212] *
SAIKO ET AL: "Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad?", MUTATION RESEARCH. REVIEWS IN MUTATION RESEARCH, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.MRREV.2007.08.004, vol. 658, no. 1-2, 1 January 2008 (2008-01-01), pages 68 - 94, XP022441374, ISSN: 1383-5742 *
VELLA R ET AL: "Prevention of Cardiovascular Damage in Hypertensive Rats by Resveratrol", HEART, LUNG AND CIRCULATION, ELSEVIER LNKD- DOI:10.1016/J.HLC.2008.05.581, vol. 17, 1 January 2008 (2008-01-01), pages S232 - S233, XP022852482, ISSN: 1443-9506, [retrieved on 20080101] *
VELLA R ET AL: "Prevention of Inflammation, Oxidative Stress and Cardiovascular Damage in Rat Models of Hypertension and Diabetes by Resveratrol", HEART, LUNG AND CIRCULATION, ELSEVIER LNKD- DOI:10.1016/J.HLC.2009.05.491, vol. 18, 1 January 2009 (2009-01-01), pages S317, XP026304209, ISSN: 1443-9506, [retrieved on 20090101] *

Also Published As

Publication number Publication date
JP2013518034A (en) 2013-05-20
WO2011089168A2 (en) 2011-07-28
CA2792993A1 (en) 2011-07-28
EP2525791A2 (en) 2012-11-28
US20130029996A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
JOP20180102B1 (en) Pharmaceutical composition
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL235767A (en) Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof
WO2014093747A3 (en) Antiperspirant and deodorant compositions
IL216254A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
WO2012077120A3 (en) Natural formulations
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
IL225824A0 (en) Quinoxaline derivatives, their preparation and pharmaceutical compositions containing them
WO2011122869A3 (en) Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
IL226094A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
IL229204A (en) Prenylated hydroxystilbenes, pharmaceutical compositions and uses thereof
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
PL2654762T3 (en) Extract of the aerial parts of gynandropsis gynandra and cosmetic, dermatoligic and pharmaceutic compositions comprising the extract
PL2646520T3 (en) Compositions containing 1,1,1,4,4,4-hexafluorobut-2-ene and 3,3,4,4,4- pentafluorobut-1-ene
EP2687549A4 (en) Lipophilic, highly branched polymer, and photopolymerizable composition containing the same
EP2929786A4 (en) Composition comprising natural polyphenol compounds, and composition for oral administration comprising same
IL225440A (en) Cyclohexane derivatives, compositions comprising the same and uses thereof
IL225724A0 (en) Acylbenzene derivatives, compositions comprising the same and uses thereof
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
IL225823A0 (en) Quinaoline derivatives, their preparation and pharmaceutical compositions containing them
MX2014006574A (en) Acamprosate formulations, methods of using the same, and combinations comprising the same.
WO2011089168A3 (en) Special composition for the use thereof as a drug
WO2012036414A3 (en) Cosmetic composition comprising a fermented soybean extract fraction as an active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11700445

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2792993

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012549351

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011700445

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011700445

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13574012

Country of ref document: US